Cytokinetics to Participate in May Investor Conferences

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) has announced its participation in two major investor conferences this May. The company will engage in fireside chats at:

• The Citizens Life Sciences Conference on May 7, 2025, at 10:00 AM ET at the New York Hilton Midtown Hotel
• The 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 8:30 AM ET at the InterContinental New York Barclay Hotel

Both fireside chats will be accessible via live webcasts through the Investors & Media section of Cytokinetics' website. Recordings will remain available for 90 days after the events.

Positive

• Management team's active participation in two major healthcare investor conferences indicates strong investor relations efforts
• Live webcasts of presentations made accessible to all investors shows transparency and broad market engagement

Negative

• None.

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in May:

• The Citizens Life Sciences Conference: Members of the management team will participate in a fireside chat on Wednesday, May 7, 2025 at 10:00 AM Eastern Time at the New York Hilton Midtown Hotel in New York, NY.
• 2025 RBC Capital Markets Global Healthcare Conference: Members of the management team will participate in a fireside chat on Wednesday, May 21, 2025 at 8:30 AM Eastern Time at the InterContinental New York Barclay Hotel in New York, NY.

Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

When will Cytokinetics (CYTK) present at the Citizens Life Sciences Conference in May 2025?

Cytokinetics will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 10:00 AM Eastern Time at the New York Hilton Midtown Hotel.

Where can I watch Cytokinetics (CYTK) May 2025 investor conference webcasts?

The live webcasts can be accessed through the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. Replays will be available for 90 days after the events.

Which investor conferences is CYTK attending in May 2025?

CYTK is attending two conferences: The Citizens Life Sciences Conference on May 7 and the RBC Capital Markets Global Healthcare Conference on May 21, 2025.

What time is Cytokinetics' (CYTK) presentation at the RBC Healthcare Conference?

Cytokinetics will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:30 AM Eastern Time in New York.

How long will CYTK's May 2025 investor conference webcasts be available for replay?

The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of each event.